600161 天坛生物
已收盘 12-05 15:00:00
资讯
新帖
简况
天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%
证券之星 · 12-04 22:14
天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%
天坛生物(600161.SH)下属企业获得临床试验总结报告
智通财经 · 12-04 17:15
天坛生物(600161.SH)下属企业获得临床试验总结报告
天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%
证券之星 · 11-24
天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%
每周股票复盘:天坛生物(600161)现2751万元大宗交易
证券之星 · 11-23
每周股票复盘:天坛生物(600161)现2751万元大宗交易
天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请
智通财经 · 11-19
天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请
每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易
证券之星 · 11-09
每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易
11月7日天坛生物发生1笔大宗交易 成交金额2210.4万元
证券之星 · 11-07
11月7日天坛生物发生1笔大宗交易 成交金额2210.4万元
天坛生物“增收不增利” 血液制品龙头遭遇增长阵痛
新浪证券 · 11-07
天坛生物“增收不增利” 血液制品龙头遭遇增长阵痛
天坛生物(600161)披露召开2025年第三季度业绩说明会公告,11月04日股价上涨0.16%
证券之星 · 11-04
天坛生物(600161)披露召开2025年第三季度业绩说明会公告,11月04日股价上涨0.16%
天坛生物(600161)2025年三季报简析:增收不增利
证券之星 · 10-26
天坛生物(600161)2025年三季报简析:增收不增利
天坛生物前三季度净利8.19亿元,同比下降22.16%
北京商报 · 10-24
天坛生物前三季度净利8.19亿元,同比下降22.16%
天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%
证券之星 · 10-21
天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%
天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验
证券之星 · 10-21
天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验
每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证
证券之星 · 10-12
每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证
天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%
证券之星 · 10-09
天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%
天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书
证券之星 · 09-30
天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书
每周股票复盘:天坛生物(600161)子公司获GMP符合性认证
证券之星 · 09-28
每周股票复盘:天坛生物(600161)子公司获GMP符合性认证
天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书
智通财经 · 09-22
天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书
每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)
证券之星 · 09-21
每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)
天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%
证券之星 · 09-18
天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%
加载更多
公司概况
公司名称:
北京天坛生物制品股份有限公司
所属行业:
医药制造业
上市日期:
1998-06-16
主营业务:
北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。
发行价格:
4.07
{"stockData":{"symbol":"600161","market":"SH","secType":"STK","nameCN":"天坛生物","latestPrice":17.1,"timestamp":1764918001000,"preClose":17,"halted":0,"volume":7344592,"delay":0,"changeRate":0.0059,"floatShares":1977000000,"shares":1977000000,"eps":0.6656,"marketStatus":"已收盘","change":0.1,"latestTime":"12-05 15:00:00","open":17,"high":17.11,"low":16.86,"amount":125000000,"amplitude":0.0147,"askPrice":17.1,"askSize":483,"bidPrice":17.09,"bidSize":253,"shortable":0,"etf":0,"ttmEps":0.6656,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":17,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":18.7,"lowLimit":15.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1977371446,"isCdr":false,"pbRate":2.95,"roa":"--","peRate":25.691106,"roe":"7.16%","epsLYR":0.78,"committee":0.210962,"marketValue":33813000000,"turnoverRate":0.0037,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-12-08。","floatMarketCap":33813000000},"requestUrl":"/m/hq/s/600161","defaultTab":"news","newsList":[{"id":"2588809498","title":"天坛生物(600161)披露下属企业获得临床试验总结报告,12月04日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588809498","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588809498?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:14","pubTimestamp":1764857666,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘,天坛生物报收于17.0元,较前一交易日下跌0.93%,最新总市值为336.15亿元。该股当日开盘17.16元,最高17.17元,最低16.99元,成交额达1.08亿元,换手率为0.32%。近日,天坛生物发布公告称,公司下属国药集团贵州生物制药有限公司研制的人凝血酶原复合物已完成Ⅲ期临床试验并取得临床试验总结报告。临床试验结果显示,该产品可显著提升凝血因子水平,改善出血症状,具有良好的安全性和有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0185","BK0082","BK0188","BK0028","BK0046","BK0168","BK0239","BK0010"],"gpt_icon":0},{"id":"2588007689","title":"天坛生物(600161.SH)下属企业获得临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2588007689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588007689?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:15","pubTimestamp":1764839718,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)发布公告,近日,公司下属国药集团贵州生物制药有限公司(简称“天坛贵州”)研制的“人凝血酶原复合物”完成了Ⅲ期临床试验并取得临床试验总结报告。天坛贵州生产的人凝血酶原复合物临床试验结果显示,输注后能显著提升血友病B患者的凝血因子Ⅱ/Ⅶ/Ⅸ/Ⅹ水平、提高血友病B患者的凝血功能,改善血友病B患者的出血症状和体征,对血友病B患者具有良好的疗效。同时安全性分析结果显示,该药物在临床应用过程中对血友病B患者具有良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0046","BK0168","600161","BK0010","BK0185","BK0028","BK0082","BK0239"],"gpt_icon":0},{"id":"2585604054","title":"天坛生物(600161)披露控股股东权益变动提示性公告,11月24日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585604054","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585604054?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993635,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,天坛生物报收于17.66元,较前一交易日上涨0.28%,最新总市值为349.2亿元。该事项已获实际控制人中国医药集团有限公司批复。本次划转完成后,中国生物将直接持有公司921,302,854股股份,占总股本46.59%,北京所不再持有公司股份。中国生物及其一致行动人合计持股数量和比例保持不变,均为991,120,289股、50.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0188","BK0010","600161","BK0168","BK0185","BK0046","BK0028","BK0239"],"gpt_icon":0},{"id":"2585103318","title":"每周股票复盘:天坛生物(600161)现2751万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103318?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:13","pubTimestamp":1763835191,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,天坛生物报收于17.61元,较上周的18.59元下跌5.27%。本周,天坛生物11月17日盘中最高价报18.62元。本周关注点交易信息汇总:11月17日天坛生物现2751万元大宗交易。交易信息汇总11月17日天坛生物现2751万元大宗交易公司公告汇总北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司研发的注射用重组人凝血因子Ⅶa,因需补充儿童患者群体临床试验数据,已向国家药品监督管理局药品审评中心提出撤回上市许可申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","600161","BK0185","BK0028","BK0010","BK0082","BK0046","BK0188","BK0239"],"gpt_icon":0},{"id":"2584791162","title":"天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2584791162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584791162?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:10","pubTimestamp":1763543409,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)发布公告,北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司(以下简称 “成都蓉生”)研发的“注射用重组人凝血因子Ⅶa”于2025年1月向国家药品监督管理局药品审评中心(CDE)递交上市许可申请,并获得《受理通知书》(受理号:CXSS2500005)。自获得该产品上市许可申请受理以来,成都蓉生持续开展配合审评相关工作。近日,根据CDE审评意见,该产品需补充儿童(<12岁)患者群体的临床试验相关数据。据此,成都蓉生向CDE提出了药品注册撤回申请,将在补充完善相关临床数据工作后,重新提交药品上市许可注册申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"天坛生物(600161.SH):撤回注射用重组人凝血因子Ⅶa药品注册申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0082","BK0028","BK0188","BK0239","600161","BK0010","BK0168","BK0185"],"gpt_icon":0},{"id":"2582869654","title":"每周股票复盘:天坛生物(600161)11月7日发生2210.4万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2582869654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582869654?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:40","pubTimestamp":1762627225,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,天坛生物报收于18.42元,较上周的18.43元下跌0.05%。本周,天坛生物11月4日盘中最高价报18.54元。11月3日盘中最低价报18.32元。天坛生物当前最新总市值364.23亿元,在生物制品板块市值排名9/51,在两市A股市值排名504/5166。投资者可于2025年11月5日至11月11日16:00前通过上证路演中心“提问预征集”栏目或公司投资者关系邮箱ttswdb@sinopharm.com提交问题。说明会期间,投资者可登录上证路演中心在线参与并提问。联系部门:董事会办公室;电话:010-65439720。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0185","BK0082","BK0188","BK0028","BK0046","BK0168","BK0239","BK0010"],"gpt_icon":0},{"id":"2581008463","title":"11月7日天坛生物发生1笔大宗交易 成交金额2210.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581008463","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581008463?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:21","pubTimestamp":1762507292,"startTime":"0","endTime":"0","summary":"证券之星消息,11月7日天坛生物发生大宗交易,交易数据如下:大宗交易成交价格18.42元,成交120万股,成交金额2210.4万元,买方营业部为国泰海通证券股份有限公司总部,卖方营业部为中国国际金融股份有限公司上海分公司。近三个月该股共发生1笔大宗交易,合计成交1.2万手。截至2025年11月7日收盘,天坛生物报收于18.42元,上涨0.11%,换手率0.34%,成交量6.74万手,成交额1.24亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700027569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0046","600161","BK0168","BK0185","BK0010","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2581890008","title":"天坛生物“增收不增利” 血液制品龙头遭遇增长阵痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2581890008","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581890008?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:16","pubTimestamp":1762506960,"startTime":"0","endTime":"0","summary":"作为中国血液制品行业的龙头企业之一,天坛生物近年来一直以高增长姿态示人。然而,其2025年三季度报告却显示公司陷入“增收不增利”的尴尬局面,归母净利润同比大幅下降42.84%,经营现金流净额暴跌91%,引发市场广泛关注。过去三年,天坛生物净利润增速均保持在15%以上,2024年甚至接近40%。 天坛生物的利润下滑,并非孤例,而是整个血液制品行业在集采、成本与技术三重变革下的缩影。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-07/doc-infwqkxv1004054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0168","BK0046","BK0185","BK0010","BK0028","BK0188","BK0239","BK0082","600161"],"gpt_icon":0},{"id":"2580992758","title":"天坛生物(600161)披露召开2025年第三季度业绩说明会公告,11月04日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580992758","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580992758?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:24","pubTimestamp":1762266274,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘,天坛生物报收于18.5元,较前一交易日上涨0.16%,最新总市值为365.81亿元。近日,天坛生物发布关于召开2025年第三季度业绩说明会的公告。公告称,北京天坛生物制品股份有限公司将于2025年11月12日9:30-10:30通过上海证券交易所上证路演中心举行2025年第三季度业绩说明会,就公司前三季度经营成果、财务状况等情况与投资者进行网络互动交流。说明会期间,投资者可登录上证路演中心在线参与并提问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0046","BK0185","BK0010","BK0028","BK0188","BK0239","BK0082","600161"],"gpt_icon":0},{"id":"2578833976","title":"天坛生物(600161)2025年三季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2578833976","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578833976?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:01","pubTimestamp":1761429673,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期天坛生物发布2025年三季报。根据财报显示,天坛生物增收不增利。截至本报告期末,公司营业总收入44.65亿元,同比上升9.62%,归母净利润8.19亿元,同比下降22.16%。按单季度数据看,第三季度营业总收入13.55亿元,同比上升9.96%,第三季度归母净利润1.86亿元,同比下降42.84%。本次财报公布的各项数据指标表现一般。去年的净利率为35.02%,算上全部成本后,公司产品或服务的附加值极高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0188","600161","BK0046","BK0028","BK0168","BK0010","BK0185","BK0239"],"gpt_icon":0},{"id":"2577192655","title":"天坛生物前三季度净利8.19亿元,同比下降22.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577192655","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577192655?lang=zh_cn&edition=full","pubTime":"2025-10-24 20:07","pubTimestamp":1761307620,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)10月24日晚间,天坛生物(600161)发布2025年三季报显示,公司前三季度营业收入44.65亿元,同比增长9.62%;归属净利润8.19亿元,同比下降22.16%。天坛生物表示,报告期内,销售价格下降,同时受信用政策影响,信用减值损失增加,归属净利润下降。(文章来源:北京商报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuyzvk6807746.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuyzvk6807746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0168","BK0188","BK0082","BK0028","600161","BK0010","BK0046","BK0185"],"gpt_icon":0},{"id":"2577871661","title":"天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577871661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577871661?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:32","pubTimestamp":1761057134,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘,天坛生物报收于19.08元,较前一交易日上涨0.42%,最新总市值为377.28亿元。该股当日开盘19.01元,最高19.12元,最低18.96元,成交额达1.29亿元,换手率为0.34%。公司近日发布公告称,其下属国药集团武汉生物制药有限公司研制的“人凝血酶原复合物”已完成临床伦理审查及入组前准备工作,近日正式开展Ⅲ期临床试验。该产品后续仍需完成Ⅲ期临床试验、提交上市申请并经审评审批,存在不确定性,提醒投资者注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100037139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0046","600161","BK0168","BK0185","BK0010","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2577001823","title":"天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2577001823","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577001823?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:40","pubTimestamp":1761039625,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司下属国药集团武汉生物制药有限公司研制的人凝血酶原复合物已完成临床伦理审查、临床入组前准备等工作,于近日正式开展Ⅲ期临床试验。该产品主要用于治疗先天性和获得性凝血因子Ⅱ、Ⅶ、Ⅸ和Ⅹ缺乏症,包括血友病B、抗凝剂过量、维生素K缺乏症等。目前国内市场已有多家企业生产该产品,国际市场也有多家跨国企业生产。但该产品后续尚需完成Ⅲ期临床试验、提交药品上市许可申请等程序,存在诸多内外部不确定因素,敬请广大投资者注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100027380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","600161","BK0185","BK0028","BK0010","BK0082","BK0046","BK0188","BK0239"],"gpt_icon":0},{"id":"2574579044","title":"每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2574579044","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574579044?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:50","pubTimestamp":1760205022,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,天坛生物报收于19.36元,较上周的19.08元上涨1.47%。本周,天坛生物10月10日盘中最高价报19.38元。本周关注点公司公告汇总:成都蓉生获《药品GMP符合性检查告知书》,可扩大重组人凝血因子Ⅷ生产规模公司公告汇总天坛生物下属成都蓉生药业有限责任公司收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》及变更后的《药品生产许可证》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0082","BK0188","BK0046","BK0168","600161","BK0010","BK0239"],"gpt_icon":0},{"id":"2574169361","title":"天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574169361","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574169361?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:44","pubTimestamp":1760021061,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘,天坛生物报收于19.28元,较前一交易日上涨1.05%,最新总市值为381.24亿元。该股当日开盘19.13元,最高19.31元,最低19.01元,成交额达2.5亿元,换手率为0.66%。公司近日发布公告称,其下属成都蓉生药业有限责任公司收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》和变更后的《药品生产许可证》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900034716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0082","BK0010","600161","BK0168","BK0188","BK0185","BK0028"],"gpt_icon":0},{"id":"2571310793","title":"天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571310793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571310793?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:19","pubTimestamp":1759223973,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司下属企业国药集团昆明血液制品有限公司于2025年9月28日获得国家药品监督管理局签发的《药物临床试验批准通知书》,同意开展“人纤维蛋白原”临床试验。该产品主要用于先天性纤维蛋白原减少或缺乏症以及获得性纤维蛋白原减少症,包括严重肝脏损伤、肝硬化、弥散性血管内凝血、产后大出血等。产品规格为0.5g(25ml)/瓶,剂型为注射剂。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000028162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0082","BK0010","600161","BK0188","BK0168","BK0185","BK0239"],"gpt_icon":0},{"id":"2570894456","title":"每周股票复盘:天坛生物(600161)子公司获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2570894456","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570894456?lang=zh_cn&edition=full","pubTime":"2025-09-28 04:01","pubTimestamp":1759003277,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘,天坛生物报收于19.02元,较上周的19.37元下跌1.81%。本周,天坛生物9月22日盘中最高价报19.44元。本周关注点公司公告汇总:成都蓉生药业收到《药品GMP符合性检查告知书》,生产条件获监管认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0046","600161","BK0168","BK0185","BK0010","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2569785351","title":"天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2569785351","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569785351?lang=zh_cn&edition=full","pubTime":"2025-09-22 18:14","pubTimestamp":1758536076,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)公告,公司下属成都蓉生药业有限责任公司(简称“成都蓉生”)收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》,涉及车间为:重组产品生产车间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0046","BK0010","BK0082","BK0185","600161","BK0168","BK0239"],"gpt_icon":0},{"id":"2569078243","title":"每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569078243","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569078243?lang=zh_cn&edition=full","pubTime":"2025-09-21 02:39","pubTimestamp":1758393552,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,天坛生物报收于19.37元,较上周的19.73元下跌1.82%。本周,天坛生物9月18日盘中最高价报19.75元。本周关注点公司公告汇总:天坛生物拟每股派发现金红利0.15元(含税),股权登记日为2025年9月24日。本次利润分配以公司总股本1,977,371,446股为基数,共派发现金红利296,605,716.90元(含税)。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","600161","BK0010","BK0168","BK0185","BK0188","BK0082"],"gpt_icon":0},{"id":"2568054004","title":"天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568054004","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568054004?lang=zh_cn&edition=full","pubTime":"2025-09-18 22:35","pubTimestamp":1758206121,"startTime":"0","endTime":"0","summary":"截至2025年9月18日收盘,天坛生物报收于19.58元,较前一交易日下跌0.05%,最新总市值为387.17亿元。该股当日开盘19.58元,最高19.75元,最低19.44元,成交额达2.94亿元,换手率为0.76%。公司近日发布《2025年半年度权益分派实施公告》,宣布本次利润分配方案为每股派发现金红利0.15元(含税)。股权登记日为2025年9月24日,除权(息)日和现金红利发放日均为2025年9月25日。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800037611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0046","BK0010","BK0082","BK0185","600161","BK0168","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765097979810,"stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0727},{"period":"3month","weight":-0.13},{"period":"6month","weight":-0.1401},{"period":"1year","weight":-0.1742},{"period":"ytd","weight":-0.1548}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京天坛生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79044人(较上一季度增加1.50%)","perCapita":"25016股","listingDate":"1998-06-16","address":"北京市大兴区北京经济技术开发区博兴二路6号院8号楼521室","registeredCapital":"197737万元","survey":" 北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。","listedPrice":4.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天坛生物,600161,天坛生物股票,天坛生物股票老虎,天坛生物股票老虎国际,天坛生物行情,天坛生物股票行情,天坛生物股价,天坛生物股市,天坛生物股票价格,天坛生物股票交易,天坛生物股票购买,天坛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}